(-0.06%) 5 475.00 points
(-0.11%) 38 776 points
(-0.03%) 19 916 points
(0.20%) $80.49
(1.26%) $2.82
(0.27%) $2 335.20
(-0.11%) $29.36
(-0.21%) $968.90
(0.01%) $0.932
(-0.16%) $10.64
(0.06%) $0.788
(-1.87%) $86.79
Live Chart Being Loaded With Signals
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer...
Stats | |
---|---|
Šios dienos apimtis | 2.74M |
Vidutinė apimtis | 1.03M |
Rinkos kapitalizacija | 479.65M |
EPS | $-0.900 ( Q4 | 2024-05-16 ) |
Kita pelno data | ( $-0.880 ) 2024-08-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-2.41 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0170 (0.22%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-07 | Xynos Konstantinos | Sell | 15 881 | Common Stock |
2024-05-16 | Sarchi Christopher | Sell | 2 218 | Common Stock |
2024-05-16 | Schwendenman Andrew | Sell | 2 298 | Common Stock |
2024-05-16 | Love Colin | Sell | 17 615 | Common Stock |
2024-05-16 | Astley-sparke Philip | Sell | 37 928 | Common Stock |
INSIDER POWER |
---|
64.97 |
Last 98 transactions |
Buy: 2 561 803 | Sell: 548 134 |
Tūris Koreliacija
Replimune Group Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
FIVE | 0.89 |
VERV | 0.876 |
QTRX | 0.87 |
EDIT | 0.861 |
ALKS | 0.86 |
WKHS | 0.86 |
RKDA | 0.859 |
CDZIP | 0.853 |
PTPI | 0.853 |
ATRC | 0.85 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Replimune Group Inc Koreliacija - Valiuta/Žaliavos
Replimune Group Inc Finansinės ataskaitos
Annual | 2024 |
Pajamos: | $0 |
Bruto pelnas: | $-2.66M (0.00 %) |
EPS: | $-3.24 |
FY | 2024 |
Pajamos: | $0 |
Bruto pelnas: | $-2.66M (0.00 %) |
EPS: | $-3.24 |
FY | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $-2.45M (0.00 %) |
EPS: | $-2.99 |
FY | 2022 |
Pajamos: | $0 |
Bruto pelnas: | $-4.58M (0.00 %) |
EPS: | $-2.26 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Replimune Group Inc
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.